Stander S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, Williams N, Sciascia T, Augustin M. Worst itch numerical rating scale for Prurigo Nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022 Apr;36(4):573-81. doi: 10.1111/jdv.17870
Sulyok CJ, Fox L, Ritchie H, Lanzas C, Lenhart S, Day J. Mathematically modeling the effect of touch frequency on the environmental transmission of Clostridioides difficile in healthcare settings. Math Biosci. 2021 Oct;340:108666. doi: 10.1016/j.mbs.2021.108666
Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Smith RB, Bennett JE, Rantakokko P, Martinez D, Nieuwenhuijsen MJ, Toledano MB. The relationship between MX [3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone], routinely monitored trihalomethanes, and other characteristics in drinking water in a long-term survey. Environ Sci Technol. 2015 Jun 2;49(11):6485-93. doi: 10.1021/es5062006
Perez L, Medina-Ramon M, Kunzli N, Alastuey A, Pey J, Perez N, Garcia R, Tobias A, Querol X, Sunyer J. Size fractionate particulate matter, vehicle traffic, and case-specific daily mortality in Barcelona, Spain. Environ Sci Technol. 2009 Jul 1;43(13):4707-14. doi: 10.1021/es8031488
McKennas SP, Whalley D, deProst Y, Staab D, Huels J, Paul CF, vanAssche D. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006 Mar 1;20(3):248-54.
Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P. Measuring quality of life in lupus: development of the SLEQoL. Poster presented at the First EADV International Spring Symposium; February 2003. [abstract] J Eur Acad Dermatol Venereol. 2003 Mar; 17(Suppl 1):58.
Poulos C, Whittington D. Time preferences for life-saving programs: evidence from six less developed countries. Environ Sci Technol. 2000 Apr 15;34(8):1445-55.